Liephar SA
3.1 FTEThe score of Liephar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +20 % Total assets +58 % Headcount (avg FTE) +48 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Liephar's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 73,219 € | ||||
| Equity | 846,006 € | ||||
| Cash | 182,497 € | ||||
| EBITDA | 203,863 € | ||||
| Total assets | €1.59m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Jul 2026
- Year ended 31 Dec 2024filed on 30 Jul 2025
- Year ended 31 Dec 2023filed on 21 Aug 2024
- Year ended 31 Dec 2022filed on 01 Sep 2023
- Year ended 31 Dec 2021filed on 13 Jul 2022
Liephar's financial analysis
- Solvency53.3%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Liephar
Liephar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0862.571.213
- VAT number
- BE0862571213
- Peppol
- Registered · 0208:0862571213 · as of 06 Nov 2026
- Legal form
- SA
- Incorporated
- 12 Jan 2004
- Registered office
- 5640 Mettet
- Size
- Micro · 3.1 FTE
- Latest accounts
- 2025 · filed on 30 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Liephar (SA) has been based in Mettet since 2004, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 73,219 € and equity of 846,006 €; its revenue is not published. With 3.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 53.3%, above the median of its sector (41.5%).
Companies similar to Liephar
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie Dehaut Retail sale of pharmaceutical products Dour · balance sheet €1.59m
- Apotheek Veltem_Pharma Retail sale of pharmaceutical products Herent · balance sheet €1.59m
- Amicus - C Retail sale of pharmaceutical products Antwerp · balance sheet €1.58m
- Decaphar Retail sale of pharmaceutical products Oudenaarde · balance sheet €1.58m
- Dekerk Kumtich Retail sale of pharmaceutical products Tienen · balance sheet €1.60m
- DE-Pharma Retail sale of pharmaceutical products Mons · balance sheet €1.60m
- Lovafarma Retail sale of pharmaceutical products Leuven · balance sheet €1.60m
- Heerse Apotheek Retail sale of pharmaceutical products Heers · balance sheet €1.57m
Frequently asked questions about Liephar
What is the revenue of Liephar?
Liephar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Liephar?
In Belgium, the VAT number is the company number prefixed with BE: BE0862571213 for Liephar, if the company is VAT-registered. Its company number (CBE) is 0862.571.213.
Where is the registered office of Liephar?
According to the CBE register, the registered office of Liephar is in 5640 Mettet.
What is the equity of Liephar?
At the close of the 2025 financial year, the equity of Liephar amounts to 846,006 €, a solvency of 53.3% of total assets.
How many people work at Liephar?
3.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Liephar?
The register lists 4 active mandates at Liephar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Liephar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →